

## Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF

Imruetaicharoenchoke, Waraporn; Fletcher, Alice; Lu, Wenqi; Watkins, RJ; Modasia, Bhavika; Poole, Vikki; Nieto, Hannah; Thompson, Rebecca; Boelaert, Kristien; Read, Martin; Smith, Vicki; McCabe, Christopher

DOI:  
[10.1530/ERC-16-0340](https://doi.org/10.1530/ERC-16-0340)

License:  
Other (please specify with Rights Statement)

*Document Version*  
Peer reviewed version

*Citation for published version (Harvard):*  
Imruetaicharoenchoke, W, Fletcher, A, Lu, W, Watkins, RJ, Modasia, B, Poole, V, Nieto, H, Thompson, R, Boelaert, K, Read, M, Smith, V & McCabe, C 2017, 'Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF', *Endocrine-related cancer*, vol. 24, no. 9, pp. 459-474.  
<https://doi.org/10.1530/ERC-16-0340>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Disclaimer: this is not the definitive version of record of this article. This manuscript has been accepted for publication in *Endocrine-Related Cancer*, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no responsibility for any errors or omissions it may contain. The definitive version is now freely available at [10.1530/ERC-16-0340] [2017].

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Table 1**

<b>PBF mutation</b>	<b>Gender</b>	<b>Age</b>	<b>Tumour origin</b>	<b>Histology</b>	<b>TNM</b>	<b>Vascular invasion</b>	<b>Zygoty</b>
<b>C51R</b>	F	66	Colon	Adenocarcinoma, poorly diff.	T4bN0M0	-	Heterozygous
<b>V55I</b>	M	54	Prostate	Carcinoma	Unknown	Unknown	Unknown
<b>W59F</b>	F	71	Lung	Adenocarcinoma, acinar type	T2aN0M0	Unknown	Unknown
<b>R87C</b>	F	58	Colon	Adenocarcinoma, moderately diff.	T3N0M0	-	Heterozygous
<b>S103L</b>	M	70	Colon	Adenocarcinoma, moderately diff.	T3N2aM0	+	Heterozygous
<b>G106R</b>	F	63	Ovary	Serous carcinoma	Unknown	Unknown	Heterozygous
<b>G106V1</b>	M	68	Colon	Adenocarcinoma, moderately diff.	TxN1bM0	-	Heterozygous
<b>G106V2</b>	M	45	Colon	Adenocarcinoma, moderately diff.	T3N0M0	-	Heterozygous
<b>G106W</b>	F	45	Colon	Adenocarcinoma, well diff.	T3N0M0	+	Heterozygous
<b>R140W</b>	F	58	Colon	Adenocarcinoma, moderately diff.	T3N0M0	-	Heterozygous
<b>R146W</b>	M	78	Colon	Adenocarcinoma, moderately to poorly diff.	T2N0M0	-	Heterozygous